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Abstract

The number of patients experiencing agitation, delirium, or opiate withdrawal
symptoms is increasing exponentially. Geriatric delirium is a condition that
can be difficult to treat. The epidemic of opiate use, and subsequent
withdrawal sequela, presents as psychosis, agitation, combativeness.
Treatment of these symptoms using antipsychotic drugs is not without
complications. One possible medication side effect, Neuroleptic Malignant
Syndrome (NMS), is characterized as a life-threatening emergency whose
presenting symptoms include a decreased level of consciousness, muscle
rigidity, neuroleptic malignant hyperthermia and autonomic dysfunction.
Identification of NMS is often overlooked in lieu of more routine conditions
such as seizure, sepsis, delirium and withdrawal agitation. Delay in the
identification and definitive treatment of NMS can be life-threatening. This
offering will present two case studies which highlight the pathophysiology
of NMS, discuss the medications implicated in its development, review
disease signs and symptoms, and outline available treatment options.
Information gained during this presentation can be incorporated within
a wide variety of settings to safely care for the neuroscience patient.

Objectives
1. Review the pathophysiology of neuroleptic malignant syndrome
(NMS) in the neuroscience patient with severe illness.
2. D
 iscuss the medications that can cause of NMS and associated
signs and symptoms.
3. Outline the treatment interventions for NMS.
4. D
 etail two case studies that illustrate the difficulty of definitive
diagnosis of NMS and the devastating consequences.

Background and Pathophysiology

1. Epidemiology
a. Incidence rate 0.02 to 3% among patients taking antipsychotic
medications
b. M
 ortality is estimated to be 10-20%
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2. Pathophysiology
a. D
 opamine receptor blockade due to medication administration
		• Hypothalamus disruption causing hyperthermia, muscle tremor,
muscle rigidity
b. G
 enetic defect of dopamine receptors
		• Defect in the sympathetic nervous system
		• Hyperexcited state can lead to hyperthermia
c. S
 tacked doses of antipsychotic drugs to lessen symptoms of
agitation, combativeness, delirium
		• Missed early signs due to diagnosis bias
		• Differential diagnoses

Covid-19: 40-year-old female

Patient transitioned to comfort measures.

Patient pronounced 6 hours after initial
temperature rise.

a. B
 aseline is confusion
b. A
 gitation and combativeness on
hospital day 2
c. F
 amily admitted patient has alcohol
dependency and severe anxiety
d. Medications over next 4 days
included Haldol, Wellbutrin, Paxil,
Ativan, Midazolam, Thiamine, Zyprexa
e. M
 uscle rigidity/shaking on hospital
day 4
f. D
 eveloped decreased level of
consciousness (stupor) and
temperature of 42.2°C (108°F).
g. Comatose
h. Dantrolene infusion/Bromocriptine
begun
i. T
 argeted temperature management

Medications that may cause neuroleptic malignant
syndrome

a. Antipsychotics: Haloperidol, Risperidone, Seroquel, Zyprexa
b. A
 ntidepressants: Wellbutrin, Amoxapine, Desipramine
c. B
 enzodiazepines: Valium, Midazolam, Ativan
d. Antiemetics: Metoclopramide, Ondansetron

Signs and symptoms of neuroleptic malignant syndrome
a. D
 ecreased level of consciousness
b. B
 ody temperature > 38°C

Treatment interventions for neuroleptic malignant syndrome
a. A
 ggressive treatment of hyperthermia
b. Iced gastric lavage
c. S
 upportive care for hemodynamic/respiratory compromise
		• Intubation with mechanical ventilation
		• Vasoactive medications to maintain MAP> 60-65
d. Dantrolene
e. Bromocriptine

Traumatic fall: 61-year-old female

a. Intubated
b. T
 oxicology – Amphetamines and
Methamphetamines
c. A
 gitation and combativeness on
hospital day 4
d. Fentanyl and Midazolam continuous
infusions
e. P
 RN doses of Diazepam and
Lorazepam
f. H
 ospital stay day 10 developed
increasing temperature. from
38.6°C (101.5°F) to 43.3°C (110°F) –
Comatose
g. D
 antrolene infusion and
Bromocriptine begun
h. T
 argeted temperature management
i. C
 ode blue protocol initiated
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